@GoldenMindTrade
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ttp://us-stemcell.com/careers/>http://us-stemcell.com/careers/
Looks like Kuwait coming online soon.....
$USRM published in Journal of Clinical MEDICAL RESEARCH THIS NOV 2017
http://www.jocmr.org/index.php/JOCMR/article/view/3187
Link to Trial here https://clinicaltrials.gov/ct2/show/NCT03226093?term=bioheart&rank=6
Enrollment: 676
Actual Study Start Date: January 1, 2015
Study Completion Date: June 1, 2017
Primary Completion Date: January 1, 2017 (Final data collection date for primary outcome measure)
& WOW talk about world wide acceptance for the use of the Stromal Vascular Fraction \/\/\/\/\/\/
http://markets.businessinsider.com/news/stocks/Tissue-Genesis-LLC-and-Human-Life-CORD-Japan-Inc-Announce-Exclusive-Agreement-to-Advance-Adult-Stem-Cell-Therapies-in-Asia-1006386674
USRM is in the same boat. Things are getting exciting.
Looking for another month of growth
ASSETS
$283k Jun 2016
$413k Sep 2016
$427k Dec 2016
$1385k Mar 2017
$1632k Jun 2017
$______ Sept 2017
Revenues
$678k Jun 2016
$729k Sep 2016
$964k Dec 2016
$1154k Mar 2017
$1386k Jun 2017 (Gross profit now $985k in Jun 2017 vs 443k last Jun 2016)
$______ Sept 2017
Cash and Cash Equivalents
$130k Jun 2016
$246k Sep 2016
$270k Dec 2016
$619k Mar 2017
$930k Jun 2017
$______Sept 2017
Revs before RMAT.
Literally no one cares. The fundamentals and market growth here say everything. :)
Big things in the works and quarterly due by next Wednesday. I asked CEO, if possible, to share growth of clinics with shareholders over the last year or two and he said "he will".
RMAT guidelines any day now as well.
It is a big deal. I guarentee you no one on this board knew how many clinics were using their products, and wow thats a lot and growing. thanks for more shares today. Looking forward to fins
"bringing the number of clinics using its technology to 287."
Missed that one buddy
$USRM
Another clinic using USRM's services with no overhead costs of actually running one. Genius. Also funny manipulation, every buy coming in is accompanied by an automatic 10k sell. It happened when I bought another $1k worth this morning and again when someone else bought 40k shares worth a little after.
1 week away :]
Cant wait to update it with Q3 :)
Im relying on straight financials and growth in a rapidly growing market. Good luck. Anything else is just extra :)
Once again its okay if you do not understand. 2 new clinics since June using USRMs services and kits. KUWAIT CLINIC BY END OF YEAR. clear as day here all you need to do is read their financials. Many a times we have pointed out the strong financial growth QoQ. Do you see stem cell banking royalties grow by 10x in year 2. Good luck once again trying to figure USRM out, it looks like the party hasnt even started yet. Looking forward to guidelines from FDA and more trials.
2 new clinics since June, and Q 3 will be out within 2 weeks :)
Spending a lot of time watching L2 arent ya buddy :). Big things here. I love this company
Im back and my timing here is almost perfect always. Been here since .045 and have flipped many times since. No positions now, but might be time to finally go long
Q3 due any day before first week of Nov. Looking forward to end of year shareholder meeting as well. Update around the corner like always too
That was a perfect bounce off mid boiler & previous resistance level at .03
Ill continue to load anything under .04
Cant hold down much longer
People realizing what is happening here. Insane the amount of effort some go to on here. Good luck all, chart looks to test new highs.
Nope that was not a T trade.:)
Wait for that .0373 smack... Its coming, this thing is moving like clockwork
Its not a scam
2 new clinis since June, Q3 due by first week of Nov. Words getting out about what $USRM has been working on. The growing revs and profit are going to grow faster and faster.
Check the dates buddy
The manuscript of the study (released Sept 28th 2017) will be published next month in the Journal of Clinical Medicine Research. Check the dates buddy http://www.jocmr.org/index.php/JOCMR/article
Will be in the Nov 2017 Journal of Clinical Medicine Research. Manuscript from Sept 28th 2017. http://www.jocmr.org/index.php/JOCMR/article/view/3187/1955
INSANE what they just released (full manuscript found here [/bhttp://www.jocmr.org/index.php/JOCMR/article/view/3187/1955 or HTMl version http://www.jocmr.org/index.php/JOCMR/article/view/3187/1954) it was submitted on "September 6, 2017, accepted September 25, 2017" Literally this is so big I dont think people understand even.
From the report
-Quick summary of what SAE and AE's stand for per the Journal of Clinical Medical Research below,
"Serious adverse events
(SAEs) are defined as any event that is fatal or life-threatening,
led to hospitalizations, or required major medical intervention.
All other events, side effects, or patient complaints/discomforts
were collected as adverse events (AEs).
Overall, the procedures demonstrated a strong safety profile
with very few reported SAEs or AEs. Figure 4 shows a summary
of the patient reported SAEs and AEs by injection type.
A total of 23 AEs and four SAEs were reported throughout the 12-month follow-up period. This corresponds to 3.4% AEs and 0.59% SAEs for SVF injections. Figure 5 shows the total
number of patients per indications with total numbers in parentheses.
Reported SAEs and AEs by indication are shown
by percentage in red. Note that some patients reported more
than one indication or disease. Patients with various neurological
diseases had greater than 84% safety profile (i.e. four
AEs out of 25 patients) indicating a very solid safety record for
intrathecal injections. Other neurological indications such as
Parkinson’s and multiple sclerosis had a higher safety percent
Conclusion
Our reported results from five treatment centers in the United
States demonstrate the overall safety of autologous stem cell
therapy using stem cells from the SVF collected from liposuction
of fat tissue. The few serious adverse side effects reported
were deemed most likely not related to stem cell therapy
received nor to the procedure used. Consequently, our paper
adds further documentation to the global safety record of adult
stem cell therapy."
Consent
All patients were consented and agreed to participate in treatments.
Competing Interests
KC is an officer of US Stem Cell, Inc.
Funding
This study was partially funded by US Stem Cell, Inc.
Author Contributions
All authors participated in clinic patient treatments and data
collection. KC analyzed the data and wrote the manuscript. All
authors read and approved the final manuscript.
Plus this in July https://www.dovepress.com/first-in-man-intraglandular-implantation-of-stromal-vascular-fraction--peer-reviewed-article-IMCRJ
20 min ago...US Stem Cell, Inc study underscores the safety of autologous #StemCell therapy in degenerative diseases and injuries https://t.co/xP3rsQnVFR https://t.co/O7C7wZZqId
Finally a PR about this. Very impressive. This will turn heads.
Financials do not lie, huge growth and the sector is just heating up
ASSETS
$283k Jun 2016
$413k Sep 2016
$427k Dec 2016
$1385k Mar 2017
$1632k Jun 2017
Revenues
$678k Jun 2016
$729k Sep 2016
$964k Dec 2016
$1154k Mar 2017
$1386k Jun 2017 (Gross profit now $985k in Jun 2017 vs 443k last Jun 2016)
On track for a ~$6mil rev year in 2018 not counting in the insane growth. 2 clinics opened since June. There will be 10 within the next 2 years..... Market cap is not correct if you ask me!!!
Cash and Cash Equivalents
$130k Jun 2016
$246k Sep 2016
$270k Dec 2016
$619k Mar 2017
$930k Jun 2017
Agreed this sector is going to be like the next MJ boom and we have a leader right here with impressive financials that are improving every quarter
Cant fight the current with a broom. USRM is going to continue to grow and prosper. Thanks :)
Minimum if you ask me this should be at least .50 cents
Could literally come whenever. Yes, no update in 2 weeks but that doesn't mean anything. I prefer the calm before the storm. The company has already been transparent month to month sometimes twice, and their last quarterly says a lot. You cant hide value like this in penny land for long :).
The amount of universities obtaining grants should be the biggest sign to everyone of wheere the market is heading. Every week another school gets a multi million dollar grant related to regenerative medicine
He is not in it for the revs. He wants a following to buy and short what he does. Having such a following makes stock move easily. Know how the system works
Check again
He must have missed the 676 patients enrolled in the saftey analysis study on Stormal Vascular Fraction (SVF) conducted by USRM and Kristin Comella. Huge developments in the works. Exciting times.
I still have not accecpted the fact this is fake. Theyre not the best but I still believe something will come out in the end. Whether it be a Rubicon, or as some others here think, a lawsuit.
USRM mentioned today in GLOBAL ANIMAL STEM CELL THERAPY MARKET 2017 – VETSTEM BIOPHARMA, MEDIVET BIOLOGIC, J-ARM
Key Players/Manufacturers Mentioned are
VETSTEM BIOPHARMA
MediVet Biologic
J-ARM
Celavet
Magellan Stem Cells
U.S. Stem Cell
Cells Power Japan
ANIMAL CELL THERAPIES
Animal Care Stem
link below
https://longshortreport.com/2017/10/04/global-animal-stem-cell-therapy-market-2017-2022/
didn't buy the full report it cost $3480